Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Cullinan Therapeutics, Inc. (CGEM : NSDQ)

• Company Description    Cullinan Therapeutics Inc. is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. The company's product pipeline consists CLN-978. Cullinan Therapeutics Inc., formerly known as Cullinan Oncology Inc., is based in CAMBRIDGE, Mass. Number of Employees: 109

• Price / Volume Information    Yesterday's Closing Price: $14.89 Daily Weekly Monthly 20 Day Moving Average: 1,088,091 shares Shares Outstanding: 64.36 (millions) Market Capitalization: $958.24 (millions) Beta: -0.05 52 Week High: $23.19 52 Week Low: $6.73 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -11.74% -12.32% 12 Week -13.48% -18.40% Year To Date 43.87% 26.96%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE MAIN STREET SUITE 1350 - CAMBRIDGE,MA 02142 USA ph: 617-410-4650 fax: - investors@cullinantx.com https://cullinantherapeutics.com

• General Corporate Information    Officers Nadim Ahmed - President; Chief Executive Officer and Director Mary Kay Fenton - Chief Financial Officer Andrew Allen - Director Mittie Doyle - Director David Meek - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 230031106 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 64.36 Most Recent Split Date: (:1) Beta: -0.05 Market Capitalization: $958.24 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.71 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.84 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 24.30% vs. Previous Quarter: -8.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - -52.89 03/31/26 - -51.45 ROA 09/30/26 - - 06/30/26 - -48.18 03/31/26 - -47.64 Current Ratio 09/30/26 - - 06/30/26 - 8.42 03/31/26 - 10.28 Quick Ratio 09/30/26 - - 06/30/26 - 8.42 03/31/26 - 10.28 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - 5.24 03/31/26 - 5.96 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©